阿帕替尼治疗晚期胃癌的疗效预测和预后分析

赵青芳; 关露露; 吕慧芳

doi:10.19401/j.cnki.1007-3639.2018.03.006

您当前的位置：

首页 >

文章列表页 >

阿帕替尼治疗晚期胃癌的疗效预测和预后分析

论著 | 更新时间：2026-01-27

- 阿帕替尼治疗晚期胃癌的疗效预测和预后分析
- Analysis of the efficacy prediction and prognostic factors for advanced gastric cancer treated with apatinib
- 中国癌症杂志 2018年28卷第3期页码：203-209
- 作者机构：
  
  郑州大学附属肿瘤医院，河南省肿瘤医院肿瘤内科,河南,郑州,450000
- 作者简介：
- 基金信息：
  
  国家自然科学基金（81472714）;河南省医学科技攻关计划重点项目（201502027）。
- DOI：10.19401/j.cnki.1007-3639.2018.03.006
  中图分类号： R735.2
- 网络出版：2018-04-11，
  
  纸质出版：2018-04-11
- 稿件说明：
移动端阅览
赵青芳,关露露,吕慧芳,等. 阿帕替尼治疗晚期胃癌的疗效预测和预后分析[J]. 中国癌症杂志, 2018, 28(3): 203-209.

赵青芳, 关露露, 吕慧芳. Analysis of the efficacy prediction and prognostic factors for advanced gastric cancer treated with apatinib[J]. China Oncology, 2018, 28(3): 203-209.
赵青芳,关露露,吕慧芳,等. 阿帕替尼治疗晚期胃癌的疗效预测和预后分析[J]. 中国癌症杂志, 2018, 28(3): 203-209. DOI： 10.19401/j.cnki.1007-3639.2018.03.006.

赵青芳, 关露露, 吕慧芳. Analysis of the efficacy prediction and prognostic factors for advanced gastric cancer treated with apatinib[J]. China Oncology, 2018, 28(3): 203-209. DOI： 10.19401/j.cnki.1007-3639.2018.03.006.

摘要

背景与目的：阿帕替尼是全球首个针对晚期胃癌的口服抗血管生成药物，随着其在临床上的广泛应用，寻找合适的疗效预测标志物及筛选敏感人群成为亟待解决的重要问题。该研究旨在观察阿帕替尼治疗晚期胃癌的疗效及安全性，寻找有效的临床预测预后因素。方法：回顾性分析2015年1月—2016年8月收治的105例晚期胃癌患者的临床资料，均给予单药口服阿帕替尼。观察指标为治疗相关不良反应、疾病控制率(disease control rate，DCR)及无进展生存期(progression-free survival，PFS)。分析临床病理特征及治疗相关不良反应与疗效及预后的关系。结果：全组患者总体中位PFS(median DFS，mPFS)为71 d(95%CI：50.1~91.9 d)，客观缓解率(objective response rate，ORR)为5.71%，DCR为65.71%。单因素分析显示，年龄大于56岁、ECOG评分0~1分、药物剂量500 mg、高血压、手足皮肤反应(hand-foot skin reaction，HFSR)、蛋白尿者PFS显著延长；而ECOG评分0~1分、药物剂量500 mg、高血压、HFSR、蛋白尿、腹泻者DCR较高。Cox和Logistic多因素分析显示，ECOG评分(P=0.007)、药物剂量(P=0.014)、高血压(P=0.012)及治疗相关HFSR(P=0.046)是阿帕替尼治疗晚期胃癌PFS的独立预后因素。ECOG评分0~1分(P=0.014)、高血压(P=0.043)及HFSR(P=0.012)与DCR高显著相关。结论：阿帕替尼治疗晚期胃癌患者具有良好的有效性和可控的安全性。ECOG评分、治疗期间出现高血压及HFSR是阿帕替尼治疗晚期胃癌DCR和PFS的独立预测因素，而药物剂量可作为PFS的独立预测因素。

Abstract

Background and purpose: Apatinib is the first oral cancer antiangiogenic drug in the world for advanced gastric cancer. With its wide application in clinics

finding suitable predictors of efficacy and screening for sensitive populations have become important issues. This study aimed to observe the efficacy and safety of apatinib in the treatment of advanced gastric cancer

and explore clinical prediction and prognostic factors. Methods: The clinicopathological features of 105 patients with advanced gastric cancer

who were treated with apatinib from Jan. 2015 to Aug. 2016

were analyzed retrospectively. All patients were given oral administration of apatinib. The indicators were treatment-related adverse reactions

disease control rate (DCR) and progression-free survival (PFS). We analyzed the relationship between clinicopathological features

treatment-related adverse reactions and prognosis. Results: The median PFS (mPFS) was 71 d (95%CI: 50.1-91.9 d)

the objective response rate was 5.71%

and DCR was 65.71%. The univariate analysis showed that PFS was significantly prolonged among patients with one of the potential prognostic factors including age of 56 years

ECOG PS 0-1

dose 500 mg

hypertension

hand-foot skin reaction (HFSR) and proteinuria. The DCR was higher among patients with one of the potential prognostic factors including ECOG PS 0-1

dose 500 mg

hypertension

HFSR

proteinuria and diarrhea. Cox and logistic multivariate analysis showed that ECOG PS

dose

hypertension

HFSR were independent prognostic factors of PFS. ECOG PS 0-1

treatment-related HFSR

hypertension were significantly associated with DCR. Conclusion: Apatinib has good efficacy and safety in the patients with advanced gastric cancer. ECOG PS

HFSR

hypertension are the favorable prognostic factors of PFS and DCR

and the drug dose can be used as an independent predictor of PFS.

关键词

Keywords

references

浏览量

2992

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

胃癌伴神经内分泌肿瘤与单纯型胃癌的免疫微环境特征比较研究

口服营养补充对胃癌根治术后存在营养风险的老年出院患者影响的前瞻性研究

胃癌领域抗肿瘤药物相关间质性肺病/肺炎的研究进展及展望

基于血清蛋白质组学的TAGLN2、CTSD等5种早期胃癌生物标志物的发现及初步验证

人工智能在胃癌诊疗和患者预后预测中的应用现状及未来展望